



Name	: Mrs. KIRSHANA W/o	UHID	: 131787	PID	: 36189
Age/Gender	: 45 Year/Female	Sample Date	: 14-Sep-2024		10:31 AM
Ref. By Dr.	: MEDIWHEEL	Report Date	: 14-Sep-2024		
Address	: ADAMPUR	Sample Type	: Inside		*36189*

Test Name	Value	Unit	Reference Range
-----------	-------	------	-----------------

HEMATOLOGY

CBC (Complete Blood Count)

Haemoglobin (Hb)	11.9	g/dl	12.0 - 15.0 g/dl
Total RBC Count	4.95	m/cumm	4.20 - 5.40
Haematocrit	42.1	%	35.0 - 50.0 %
Mean Cell Volume	85.0	fL	80.0 - 100 fL
Mean Cell Haemoglobin	28.3	pg	27.0 - 34.0 pg
Mean Cell Haemoglobin Conc	33.3	%	32.0 - 36.0
Red Cell Distribution Width (RDW)-CV	12.6	%	11.0 - 16.0 %
Red Cell Distribution Width (RDW)-SD	43.3	fL	35.0 - 56.0 fL
Total Leucocyte Count	6140	cells/cum m	4000 - 11000
Differential Leucocyte Count	.		
Neutrophils	55	%	32 - 72 %
Lymphocytes	40	%	20 - 50 %
Monocytes	3	%	2 - 11 %
Eosinophils	2	%	1 - 3 %
Basophils	0	%	0 - 2 %
Platelet Count	2,21,000	cells/cunm m	150,000 - 450,000
Platelet Distribution Width	15.7	fL	15.0 - 18.0 fL
Mean Platelet Volume	9.6	fL	7.0 - 13.0 fL

Sample Type : Whole Blood

- Spurious elevation of platelet count may be seen in patients with extensive burns, extreme microcytosis, microangiopathic hemolytic anemia, red cell fragmentation, micro-organisms like bacteria, fungi or yeast, hyperlipidemia, fragments of white blood cell (WBC) cytoplasm in patients with acute leukemia, hairy cell leukemia, lymphomas and in presence of cryoglobulins.
- Spuriously low platelet counts may be seen in cases of platelet clumping (EDTA induced, platelet cold agglutinins, multiple myeloma), platelet satellitism and in giant platelet syndromes.
- Delay in processing due to sample transport may cause a mild time dependent fall in platelet count. It is advisable to repeat the test using a citrate / heparin collection tube to avoid this pitfall.
- Automated platelet counting is subject to 10-15% variation in the result on the same as well as different analysers due to various preanalytic variables like the sampling site, skill in sample collection, anticoagulant used, sample mixing and sample transport etc.

ABO Blood Grouping

Blood Group

O⁺ POSITIVE

Haemaagglutination reaction

A Rh Positive, B Rh Positive, AB Rh Positive, O Rh Positive, A Rh Negative, B Rh Negative, AB Rh Negative, O Rh Negative

Sample Type : Whole Blood

HBA1C

HBA1C	5.1	%	4.27 - 6.00 %
-------	-----	---	---------------



Lotus Diagnostic & Imaging Centre

A Unit of Lotus Diagnostic & Imaging Solution Pvt. Ltd.

HB से लेकर MRI तक एक ही छत के नीचे

Name : Mrs. KIRSHANA W/o UHID : 131787 PID : 36189
Age/Gender : 45 Year/Female Sample Date : 14-Sep-2024 10:31 AM
Ref. By Dr. : MEDIWHEEL Report Date : 14-Sep-2024
Address : ADAMPUR Sample Type : Inside *36189*

Test Name	Value	Unit	Reference Range
-----------	-------	------	-----------------

HBA1C

turbidimetric immunoassay

Average Blood Glucose

99.67

mg/dl

90.00 - 120.00 mg/dl

turbidimetric immunoassay

Sample Type : Whole Blood

Remarks :

GLYCOSYLATED HEMOGLOBIN (HbA1c)

Reference Range : Please correlate with clinical conditions.

Bellow 6.0 % Normal value

6.0 %-7.0 % Good control

7.0 %-8.0 % Fair control

8.0 %-10 % Unsatisfactory control

Above10 % Poor control

Technology : Immunoassay and chemistry technology to measure A1C and total HB (A1C now Bayer)

AVERAGE BLOOD GLUCOSE (ABG) CALCULATED

Reference Range: Please correlate with clinical conditions.

90-120 mg/dl Excellent control

121-150 mg/d Good control

151-180 mg/dl Average control

181-210 mg/dl Action suggested

> 211 mg/dl Panic values

NOTE: Average blood glucose value is calculated from HbA1C value and it indicates average blood sugar level over past three months.

Technology: Derived from Hb A1C Values

Sample Type: Sodium heparin:

ESR

ESR	18	mmHr	0 - 20 mmHr
-----	----	------	-------------

Sample Type : Whole Blood

Dr. (Maj.)Guruprasad
MBBS, DMRD, DNB
Consultant Radiologist

Dr. Rambaksh Sharma
MBBS, MD
Consultant Radiologist

Dr. RAJESH REDDU
MBBS, DMRD
Consultant Radiologist

Dr. Amit Verma
MBBS, MD
Consultant Physician

Dr. Manish Varshney
MBBS, MD
Consultant Pathologist



Name : Mrs. KIRSHANA W/o UHID : 131787 PID : 36189
Age/Gender : 45 Year/Female Sample Date : 14-Sep-2024 10:31 AM
Ref. By Dr. : MEDIWHEEL Report Date : 14-Sep-2024
Address : ADAMPUR Sample Type : Inside *36189*

Test Name	Value	Unit	Reference Range
-----------	-------	------	-----------------

CLINICAL COMMENTS:

Erythrocyte sedimentation rate (ESR or sed rate) is a relatively simple, inexpensive, non-specific test that indirectly measures the degree of inflammation present in the body. Inflammation is part of the body's immune response. It can be acute, developing rapidly after trauma, injury or infection, for example, or can occur over an extended time (chronic) with conditions such as autoimmune diseases or cancer.

Moderately elevated ESR occurs with inflammation but also with anemia, infection, pregnancy, and with aging. A very high ESR usually has an obvious cause, such as a severe infection, marked by an increase in globulins, systemic vasculitis, polymyalgia rheumatica or temporal arteritis. People with multiple myeloma or Waldenstrom's macroglobulinemia (tumors that make large amounts of immunoglobulins) typically have very high ESRs even if they don't have inflammation.

Factors increasing ESR:

- Advanced age
- Anemia
- Pregnancy
- High fibrinogen
- Macrocytosis
- Kidney problems
- Thyroid disease
- Some cancers, such as multiple myeloma
- Infection

Factors decreasing ESR

- Microcytosis
- Low fibrinogen
- Polycythemia
- Marked leukocytosis

CLINICAL-CHEMISTRY

Glucose.Postorandial

Glucose, Post Prandial	98.4	mg/dl	70 - 140 mg/dl
Hexokinase / GOD - POD			
Sample Type : SERUM			



Name : Mrs. KIRSHANA W/o UHID : 131787 PID : 36189
Age/Gender : 45 Year/Female Sample Date : 14-Sep-2024 10:31 AM
Ref. By Dr. : MEDIWHEEL Report Date : 14-Sep-2024
Address : ADAMPUR Sample Type : Inside *36189*

Test Name	Value	Unit	Reference Range
-----------	-------	------	-----------------

Criteria for the diagnosis of diabetes (American diabetes association, 2019)

- Fasting Plasma Glucose ≥ 126 mg/dL. Fasting is defined as no caloric intake for at least 8 h.
OR
- 2-h PG ≥ 200 mg/dL during OGTT. The test should be performed using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.*
OR
- HbA1c $\geq 6.5\%$.
OR
- Random plasma glucose ≥ 200 mg/dL in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis .

Criteria defining prediabetes (American diabetes association, 2019)

- FPG 100 mg/dL to 125 mg/dL (Impaired fasting glucose, IFG)
OR
- 2-h PG during 75-g OGTT 140 mg/dL to 199 mg/dL (Impaired glucose tolerance, IGT)
OR
- HbA1c 5.7-6.4%

Note:

All abnormal results must be confirmed with a repeat test on a different day.

KIDNEY FUNCTION TEST (KFT Special)

UREA	21.9	mg/dL	14 - 45 mg/dL
KINETIC METHOD WITH UREASE AND GLDH			
CREATININE SERUM	0.9	mg/dL	0.5 - 1.4
Jaffe Kinetic			
Uric acid	5.54	mg/dL	2.5 - 6.0
Uricase - POD			
BUN SERUM	10.23	mg/dL	07 - 24
KINETIC METHOD WITH UREASE & GLDH			
SODIUM-SERUM	139.56	mmol/L	135 - 150
ISE(DIRECT)			
POTASSIUM SERUM	4.10	mmol/L	3.5 - 5.0
ISE(DIRECT)			
Chloride	104.2	mmol/L	96 - 106
Ion Selective Electrode (indirect)			
Urea / Creatinine Ratio	24.33		40:1 - 100:1
BUN / Creatinine Ratio	11.37		10:1 - 20:1
Sample Type : SERUM			



Name : Mrs. KIRSHANA W/o UHID : 131787 PID : 36189
Age/Gender : 45 Year/Female Sample Date : 14-Sep-2024 10:31 AM
Ref. By Dr. : MEDIWHEEL Report Date : 14-Sep-2024
Address : ADAMPUR Sample Type : Inside *36189*

Test Name	Value	Unit	Reference Range
-----------	-------	------	-----------------

CLINICAL COMMENTS :

UREA: High urea levels suggest poor kidney function, congestive heart failure, shock, stress, recent heart attack or severe burns; bleeding from the gastrointestinal tract; conditions that cause obstruction of urine flow; or dehydration.

Low urea levels can be seen in severe liver disease or malnutrition but are not used to diagnose or monitor these conditions. Low urea levels are also seen in normal pregnancy.

CREATININE: Increases in any renal functional impairment (intrinsic renal lesions, decreased perfusion of the kidney, or obstruction of the lower urinary tract), acromegaly and hyperthyroidism. Decreases in pregnancy, muscle wasting.

URIC ACID: Increases in case of renal failure, disseminated neoplasms, pregnancy toxemia, psoriasis, liver disease, sarcoidosis etc. Decrease is reported in Wilson's disease, Fanconi's syndrome, xanthinuria.

SODIUM: Increases due to water loss (severe diarrhea profuse sweating, polyuria or vomiting), hypergluco- or mineralo-corticoidism, and inadequate water intake. Decreases due to intake of free water or

LIVER FUNCTION TEST (LFT) (S)

Total Bilirubin-Serum	0.90	mg/dl	0.20 - 1.00 mg/dl
Bilirubin Direct Serum	0.40	mg/dl	0.10 - 0.50 mg/dl
Bilirubin Indirect-Serum	0.50	mg/dl	0.20 - 0.70 mg/dl
SGOT IFCC with Pyridoxal Phosphate	20.3	IU/L	10 - 40 IU/L
SGPT IFCC with Pyridoxal Phosphate	34.8	IU/L	07 - 56 IU/L
Alkaline Phosphatase IFCC PNPP Buffer	91.7	U/L	44 - 147 U/L
Total Protein	7.1	gm/dl	6.0 - 8.3
BIURET Albumin	4.3	g/dl	3.5 - 5.5 g/dl
BCG Globulin	2.8	gm/dl	2.0 - 3.5 gm/dl
AG RATIO	1.59		1.2 - 2.5

Sample Type : SERUM



Name : Mrs. KIRSHANA W/o UHID : 131787 PID : 36189
Age/Gender : 45 Year/Female Sample Date : 14-Sep-2024 10:31 AM
Ref. By Dr. : MEDIWHEEL Report Date : 14-Sep-2024
Address : ADAMPUR Sample Type : Inside *36189*

Test Name	Value	Unit	Reference Range
-----------	-------	------	-----------------

CLINICAL COMMENT:

Liver function tests can be suggested in case of hepatitis, liver cirrhosis and monitor possible side effects of medications. A variety of diseases and infections can cause acute or chronic damage to the liver, causing inflammation

(hepatitis), scarring (cirrhosis), bile duct obstructions, liver tumors, and liver dysfunction. Alcohol, drugs, some herbal supplements, and toxins can also injure the liver. A significant amount of liver damage may occur before symptoms such as jaundice, dark urine, light-colored stools, itching (pruritus), nausea, fatigue, diarrhea, and unexplained weight loss or gain appear. Early detection of liver injury is essential in order to minimize damage and preserve liver function.

Alanine aminotransferase (ALT) A very high level of ALT is frequently seen with acute hepatitis. Moderate increases may be seen with chronic hepatitis. People with blocked bile ducts, cirrhosis, and liver cancer may have ALT concentrations that are only moderately elevated or close to normal. Aspartate aminotransferase (AST) A very high level of AST is frequently seen with acute hepatitis. AST may be normal to moderately increased with chronic hepatitis. In people with blocked bile ducts, cirrhosis, and liver cancer, AST concentrations may be moderately increased or close to normal. When liver damage is due to alcohol, AST often increases much more than ALT (this is a

pattern seen with few other liver diseases). AST is also increased after heart attacks and with muscle injury.

AST is a less sensitive and less specific marker of liver injury than ALT. AST is more elevated than ALT in alcohol-induced liver injury. AST could be elevated more than ALT like: (i)

Lipid Profile

Cholesterol CHOD - PAP	223.92	mg/dl	<200.0 mg/dl
Triglycerides GPO - PAP	189.56	mg/dl	< 150 mg/dl
HDL Cholesterol Homogeneous Enzymatic Colorimetric test	43.21	mg/dl	Adult females >55 mg/dl
LDL Cholesterol	142.8	mg/dl	<100 mg/dl
VLDL Cholesterol	37.91	mg/dl	<30.0 mg/dl
CHO/HDL Ratio	5.18	mg/dl	Low risk 3.3-4.4
Non HDL Cholesterol Calculated	180.71	mg/dl	<130 mg/dl

Sample Type : SERUM

Interpretation

Note

- Measurements in the same patient can show physiological & analytical variations. 3 serial samples 1 wk apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
- NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogenic lipoproteins such as LDL, VLDL, IDL, Lp(a), Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL.
- Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved.
- Additional testing for Apolipoprotein B, hsCRP, Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement.

CLINICAL PATHOLOGY

PHYSICAL EXAMINATION



Lotus Diagnostic & Imaging Centre

A Unit of Lotus Diagnostic & Imaging Solution Pvt. Ltd.

HB से लेकर MRI तक एक ही छत के नीचे

Name : Mrs. KIRSHANA W/o UHID : 131787 PID : 36189
Age/Gender : 45 Year/Female Sample Date : 14-Sep-2024 10:31 AM
Ref. By Dr. : MEDIWHEEL Report Date : 14-Sep-2024
Address : ADAMPUR Sample Type : Inside *36189*

Test Name	Value	Unit	Reference Range
Colour Pale-yellow, Yellowish, Colorless, YELLOW	PALE YELLOW		
Quantity	30	ml	
pH	6.0		
Mucus Absent, Present	ABSENT		
Appearance Slightly turbid, Turbid, Clear	CLEAR		
Chemical Examination (Strip)	.		
Specific Gravity	1.020		
Albumin Absent, Present(+), Present(2+), Present(3+)	NEGATIVE		
Sugar Absent, Present(+), Present(2+), Present(3+)	NEGATIVE		
Bilirubin Absent, Present	NEGATIVE		
Microscopic Examination (Microscopy)	.		
Pus Cells	2-4	/HPF	
Epithelial Cells	1-2	/HPF	
RBC	NIL	/HPF	
Casts	ABSENT		
Crystals	ABSENT		
Bacteria	ABSENT		
Others			
Sample Type : Urine			

Laboratory

GLUCOSE FASTING

Glucose, Fasting 70.8 mg/dl 70 - 110 mg/dl
Sample Type : SERUM

Dr. (Maj.) Guruprasad
MBBS, DMRD, DNB
Consultant Radiologist

Dr. Rambaksh Sharma
MBBS, MD
Consultant Radiologist

Dr. RAJESH REDDU
MBBS, DMRD
Consultant Radiologist

Dr. Amit Verma
MBBS, MD
Consultant Physician

Dr. Manish Varshney
MBBS, MD
Consultant Pathologist



Name : Mrs. KIRSHANA W/o UHID : 131787 S No : PID : 36189
Age/Gender : 45 Year/Female A.S : NP Sample Date : 14-Sep-2024 10:31 AM
Ref. By Dr. : MEDIWHEEL Report Date : 14-Sep-2024 07:10 PM
Address : ADAMPUR Sample Type : Inside *36189*

Test Name	Value	Unit	Reference Range
-----------	-------	------	-----------------

Criteria for the diagnosis of diabetes (American diabetes association, 2019)

- Fasting Plasma Glucose ≥ 126 mg/dL. Fasting is defined as no caloric intake for at least 8 h.
OR
- 2-h PG ≥ 200 mg/dL during OGTT. The test should be performed using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.*
OR
- HbA1c $\geq 6.5\%$.
OR
- Random plasma glucose ≥ 200 mg/dL in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis .

Criteria defining prediabetes (American diabetes association, 2019)

- FPG 100 mg/dL to 125 mg/dL (Impaired fasting glucose, IFG)
OR
- 2-h PG during 75-g OGTT 140 mg/dL to 199 mg/dL (Impaired glucose tolerance, IGT)
OR
- HbA1c 5.7-6.4%

Note:

All abnormal results must be confirmed with a repeat test on a different day .

URINE SUGAR FASTING NEGATIVE

Sample Type : Urine

URINE SUGAR PP 98.1 70 - 110

Sample Type : Urine

ENDOCRINE

Thyroid Hormones (T3 .T4 & TSH)

T3	1.27	ng/ml	0.60 - 1.81 ng/ml
T4	7.73	ng/dl	5.01 - 12.45 ng/dl
TSH Ultrasensitive	3.52	uIU/ml	0.3 - 4.5 uIU/ml

Sample Type : SERUM



Lotus Diagnostic & Imaging Centre

A Unit of Lotus Diagnostic & Imaging Solution Pvt. Ltd.

HB से लेकर MRI तक एक ही छत के नीचे

Name	: Mrs. KIRSHANA W/o	UHID	: 131787	PID	: 36189
Age/Gender	: 45 Year/Female	Sample Date	: 14-Sep-2024		10:31 AM
Ref. By Dr.	: MEDIWHEEL	Report Date	: 14-Sep-2024		
Address	: ADAMPUR	Sample Type	: Inside		*36189*

Test Name	Value	Unit	Reference Range
-----------	-------	------	-----------------

Remarks :

Note1. TSH levels are subject to circadian variation, reaching peak levels between 2-4.a.m and at a minimum between 6-10 pm. The variation is of the 50 %, hence time of the day has influence on the measured serum TSH concentrations.

2. Recommended test for T3 and T4 unbound or free level as it is metabolically active.

3. Physiological rise in Total T3 and T4 level is seen in pregnancy and in patients on steroid therapy.

Clinical Use-

- * Primary Hypothyroidism
- * Hyperthyroidism
- * Hypothalamic- Pituitary hypothyroidism
- * Inappropriate-TSH secretion
- * Nonthyroidal illness
- * Autoimmune thyroid disease
- * Pregnancy associated thyroid disorders
- * Thyroid dysfunction in infancy and early childhood

--End of Report--

Dr. (Maj.) Guruprasad
MBBS, DMRD, DNB
Consultant Radiologist

Dr. Rambaksh Sharma
MBBS, MD
Consultant Radiologist

Dr. RAJESH REDDU
MBBS, DMRD
Consultant Radiologist

Dr. Amit Verma
MBBS, MD
Consultant Physician

Dr. Manish Varshney
MBBS, MD
Consultant Pathologist




Lotus Diagnostic & Imaging Centre

Age / Gender: 45/Female

Date and Time: 14th Sep 24 11:14 AM

Patient ID: 36189

Patient Name: Kriishna Kumari



AR: 64bpm

VR: 64bpm

QRSD: 78ms

QT: 388ms

QTcB: 401ms

PRI: 146ms

P-R-T: 37° -1° 67°

Sinus Rhythm, Borderline Left Ventricular Hypertrophy suspected. Please correlate clinically.





Lotus Diagnostic & Imaging Centre

A Unit of Lotus Diagnostic & Imaging Solution Pvt. Ltd.

HB से लेकर MRI तक एक ही छत के नीचे

PATIENT NAME: KRISHANA
REF. BY: TPA

AGE/SEX: 45 YRS/F
DATE: SEPTEMBER 14, 2024

X-RAY CHEST PA VIEW

- Bilateral lung parenchyma appears normal.
- Bilateral domes of diaphragm and costophrenic angles are normal.
- Cardiac and mediastinal shadow appear normal.
- Bilateral hila appear normal.
- Bony thorax and soft tissue appear normal.

Advised: Clinical correlation

Dr. Rambaksh Sharma
Consultant Radiologist

Dr. Anshul Jain
Consultant Radiologist

Dr. Rajesh Reddu
MBBS, DMRD
Consultant Radiologist

Dr. Amit Verma
Echocardiography Specialist

Dr. Sonam Aneja
Consultant Pathologist



GEETANJALI HOSPITAL

270, Gurudwara Road, Near Post Office, Model Town, Hisar, Haryana

geetanjalihospitalhisar@gmail.com | www.geetanjalihospitalhisar.com

+91-99925-64300, +91-90680 23930



H-2020-0688
Jan 11, 2023 – Jan 10, 2027
Since Jan 11, 2020

Name: Mrs. Krishna

AGE: 45 Y/F

UHID. No. 36189

Ref. by: Mediwheel

DATE: 14.09.2024

PCPNDT Reg. No.: HSR-117

USG WHOLE ABDOMEN

(Technique: USG done with 1-5 MHz convex/9 MHz linear probes in spine position)

Liver: is enlarged in size (16cm), outline and shows fatty changes (Grade-II). Hepatic vasculature is normal. IHBR are not dilated. No SOL seen.

Gall Bladder: is distended with anechoic lumen & normal wall thickness. No e/o Ac/chronic cholecystitis seen.

Portal Vein & CBD: normal in course and caliber.

Pancreas: is normal in size, outline and echotexture. PD is not dilated.

Spleen: normal in size, outline and echotexture. No focal solid/cystic lesion seen.

Right Kidney: is normal in size, shape, echotexture & outline. Corticomedullary differentiation is well maintained. No evidence of calculus/hydronephrosis seen.

Left Kidney: is normal in size, shape, echotexture & outline. Corticomedullary differentiation is well maintained. No evidence of calculus/hydronephrosis seen.

Urinary bladder: normal in distension & wall thickness. No evidence of vesicle calculus/mass seen.

Uterus: Not visualized – Post hysterectomy status.

No free fluid seen in peritoneal cavity.

Remark: 1. Non obstructing ureteric calculi are usually not visualised on USG.

2. USG is not the modality of choice for bowel pathologies and retroperitoneal evaluation.

IMPRESSION:-

- Hepatomegaly with fatty infiltration (Grade-II)

Advised: Clinical correlation

Dr. Anshul

MBBS, MD

Reg. No.: HN 21248

Consultant Radiologist

Report Typed By:- Mr. Manish Kumar (Emp. ID – 304) (Time 01:35 PM)

Patient's identity can not be ascertained at present, so this report can not be used for MLC Case.

Disclaimer: • Size & position of renal calculi may differ on different occasions. • Ureteric calculi may not be visible in absence of hydronephrosis. • Gall stones may not be visible in contracted state. • All congenital anomalies may not be detectable on routine obstetric scan. • For some foetal anomalies, serial ultrasound examination are required. • For Gynecological disease, transvaginal ultrasound (TVS) shows better results. • Not valid for medico legal purposes. • If the result (s) is/are alarming or unexpected, the patient/consultant is advised to contact Centre immediately for a recheck. • This is only a professional opinion, it may kindly be correlated clinically. • No procedure/surgery is advised on the basis of this report only. • This Report is for the purpose of doctor only.

GH/19/UE/12/06/2024